Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Income from Continuing Operations (2021 - 2025)

Krystal Biotech's Income from Continuing Operations history spans 5 years, with the latest figure at 51392000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 13.0% year-over-year to 51392000.0; the TTM value through Dec 2025 reached 204831000.0, up 129.74%, while the annual FY2025 figure was 204831000.0, 129.74% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 51392000.0 at Krystal Biotech, down from 79372000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 80747000.0 in Q3 2023 and bottomed at 49965000.0 in Q1 2022.
  • The 5-year median for Income from Continuing Operations is 7329000.0 (2021), against an average of 4768800.0.
  • The largest annual shift saw Income from Continuing Operations tumbled 215.99% in 2022 before it skyrocketed 3734.01% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 21806000.0 in 2021, then tumbled by 46.99% to 32052000.0 in 2022, then skyrocketed by 127.12% to 8692000.0 in 2023, then soared by 423.23% to 45479000.0 in 2024, then rose by 13.0% to 51392000.0 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Income from Continuing Operations are 51392000.0 (Q4 2025), 79372000.0 (Q3 2025), and 38334000.0 (Q2 2025).